PsiOxus Pursues CAR-T Mirror Image Strategy Into Clinic
Executive Summary
Bankrolled by upfront and milestone payments associated with deals it has with Bristol-Myers Squibb, Oxford, UK-based gene therapy company PsiOxus Therapeutics is targeting two INDs in 2018 and two in 2019. Company CEO John Beadle outlined his near term plans for the unpartnered programs to Scrip during the 2018 Biotech Showcase.
You may also be interested in...
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.